Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.43 |
| ▸ | GLB1 | P16278 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651943 | 0.93 | GNAO1 (0.52) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL1580535 | 0.91 | HRH3 (0.39) | GNAI3GNAO1GNAI1GLB1S1PR1 | |
| SCHEMBL4681475 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL10776413 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL9432137 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL10773791 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL9433020 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL10593959 | 0.91 | GNAO1 (0.55) | GNAI3GNAO1GNAI1S1PR1S1PR3 | |
| SCHEMBL7458771 | 0.88 | GNAI3 (0.41) | GNAI3GNAO1GNAI1GLB1S1PR1 | |
| SCHEMBL447333 | 0.85 | GNAI3 (0.46) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108931-B | Tofenamic acid derivative and preparation and application thereof | 南华大学附属第一医院 | 2024-06-14 | — | — | CN | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| CN-115108931-A | Tofenamic acid derivative and preparation and application thereof | 南华大学附属第一医院 | 2022-09-27 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| CN-108864007-B | 2-aminomethyl-6- (benzofuran-5-yl) phenol and preparation method and application thereof | 湖南大学 | 2020-08-04 | — | — | CN | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | claimed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| CN-101184758-A | Novel compounds | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| EP-0891976-B1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMA (US) | 2002-10-16 | — | — | EP | claimed |
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| EP-0598046-B1 | CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMA (US) | 1999-03-24 | — | — | EP | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-4108994-A | 5-THIAZOLE-METHANE-AMINES, AND THEIR USE AS ANTILIPOLYTICS | ROUSSEL UCLAF (FR) | 1978-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | GNAI3 3912/4885GNAO1 2970/4885GNAI1 4430/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | GNAI3 789/4885GNAO1 2031/4885GNAI1 563/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | GNAI3 1124/4885GNAO1 622/4885GNAI1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.